The use of bedaquiline in regimens to treat drug-resistant and drug-susceptible tuberculosis: a perspective from tuberculosis-affected communities

Affiliations

¹ Community Research Advisors Group, New York, NY, USA.
² Treatment Action Group, New York, NY, USA. Electronic address: mike.frick@treatmentactiongroup.org.

Laia Ruiz Mingote et al. Lancet. 2015.

. 2015 Jan 31;385(9966):477-9.

doi: 10.1016/S0140-6736(14)60523-7. Epub 2014 Jul 10.

¹ Community Research Advisors Group, New York, NY, USA.
² Treatment Action Group, New York, NY, USA. Electronic address: mike.frick@treatmentactiongroup.org.

No abstract available

Comment in

Informed use of bedaquiline for tuberculosis.
Furin J. Furin J. Lancet. 2015 May 2;385(9979):1724-1725. doi: 10.1016/S0140-6736(15)60886-8. Lancet. 2015. PMID: 25943932 No abstract available.
Informed use of bedaquiline for tuberculosis.
Lessem EM, Bernardo J, Reed C, Wegener DH. Lessem EM, et al. Lancet. 2015 May 2;385(9979):1724. doi: 10.1016/S0140-6736(15)60885-6. Lancet. 2015. PMID: 25943933 No abstract available.
Informed use of bedaquiline for tuberculosis--Authors' reply.
Mingote LR, Namutamba D, Seaworth B, Lee C, Frick MW. Mingote LR, et al. Lancet. 2015 May 2;385(9979):1725. doi: 10.1016/S0140-6736(15)60887-X. Lancet. 2015. PMID: 25943935 No abstract available.